Study Objectives: Stroke is a major neurological disease significantly threatening the human health and life with a high morbidity, disability, and mortality. Post-stroke depression (PSD) is one of the common complications of stroke. PSD has been a major factor hindering the recovery of neurological functions and daily activities in stroke patients and is closely related to the social avoidance and increased mortality of stroke patients. Although antidepressant drug treatment has improved during the last decades, symptoms in about 20% of the patients are not in remission two years after initiation of pharmacological intervention. Nowadays, non-invasive brain stimulation; techniques; transcranial direct current stimulation (tCDS) has gained an important interest in the treatment of many neuropsychiatric disorders which might be of some help in treatment of PSD. The goal of the current study is to evaluate the beneficial short term role of tDCS on post-stroke depression. Study Design: This was a randomized double blind placebo-controlled clinical trial included forty hemiparetic patients with post-stroke depression from outpatient clinic of Faculty of Physical Therapy, Cairo University, in the period between
Introduction
Stroke is the leading risk factor for severe physical disability and cognitive impairment [1] . Even if a significant number of stroke victims achieve at least some spontaneous recovery, it remains one of the main causes of permanent disability.
One of serious neuropsychiatric stroke complication, that negatively affects the therapeutic outcome, is post-stroke depression (PSD). The prevalence of PSD is 25% to 79%, depending on the setting, assessment tool, and time post-stroke [2] .
In Egypt, the prevalence of PSD in recent study was 60.78% [3] . Patients with post-stroke depression (PSD) show far less recovery from functional impairments compared with non-depressed patients with stroke.
Currently, pharmacotherapy is the most commonly prescribed and effective treatment option for major depression of all etiologies, despite the fact that approximately 30% of depressed individuals have treatment-resistant depression [4] . For individuals with PSD pharmacotherapy may be associated with increased risk of mortality and subsequent stroke. Therefore, these individuals may require novel alternative or adjunctive treatments to optimally manage the condition. Non-invasive brain stimulation (NIBS) techniques; trans Magnetic Stimulation (TMS) and transcranial direct current stimulation (tCDS) are also an alternative option, which are a non-expensive, non-invasive and relatively painless treatment [5] .
Neuronal reorganization and plasticity that follow stroke may be beneficial or maladaptive and NIBS, like tDCS, can be used to monitor and modulate this mechanism, facilitating or disrupting the neuronal activity, creating temporary or long-lasting desirable brain changes [6] . tDCS produces a subsensory level of electrical stimulation which alters neuronal resting membrane potentials to facilitate (anodal) or inhibit (cathodal) neuronal firing rates [7] . tDCS can locally reduce gamma-aminobutyric acid (GABA) neurotransmission [8] . Thus tDCS may interfere with functional connectivity, synchronization, and oscillatory activities in various cortical and subcortical networks [9] . Also, tDCS might elicit changes in non-neuronal tissues in the brain; almost all tissues and cells, including endothelial cells, lymphocytes, or glial cells [10] . tDCS relies on the application of a weak direct current of 1 -2 mA directly to the scalp through electrodes to induce regional changes in cortical excitability that can last up to a few hours after stimulation [7] . Left anterior lesions are associated with an increased risk of depression after stroke; specifically, the left dorsolateral prefrontal cortex (DLPFC) damage is correlated with more severe depression symptoms [11] . To achieve antidepressant effects, anodal tDCS is delivered over the left DLPFC (believed to be hypoactive in depression) to increase cortical excitability. Cathodal tDCS is delivered over the right DLPFC (believed to be for hyperactive in depression to decrease cortical excitability) [12] . sham stimulation in 45 patients and reported a higher response rate with active stimulation (37.5% and 20.8%, respectively) and higher remission rates (4.1%
and 0%, respectively) [15] . Several characteristics such as; noninvasiveness, absence of pharmacokinetics interactions, safety, tolerability, and low-cost make tDCS an interesting tool to be used in the treatment of psychiatric disorders [16] .
The aim of this study was to evaluate the effectiveness of tDCS in treatment of post-stroke depression.
Subject and Methods

Study Subject
This was an analytical observational study that was conducted on 40 participants 
Statistical Analysis
All data collected were tabled and statistical analyzed by using the 'Statistical Package for Social Science (SPSS) version 23. The mean and standard deviation of all scores in the two groups were calculated using descriptive statistics. The difference between scores measured before and after treatment was determined using a paired t-test. The statistical significance level (α) was set at 0.05.
Results
General Demographic Features of Both Groups (A and B)
The 
Clinical Features in Both Groups Pretreatment
Also, there were no statistical significant difference as regards sex, paretic side, Table 2 .
Comparison of the Mean Values of Hamilton Depression (HAM-D) Scale and Stroke-Specific Quality of Life (SS-QOL) Scale in Both Groups Pretreatment
There were no statistical significant difference as regards HAM-D scale and SS-QOL Scale between both groups pretreatment, P > 0.05. As, the mean value for HAM-D scale for groups A and B pretreatment were 15.30 ± 3.82 and 15.45 ± 2.70 respectively. t-value was 0.16 and P = 0.878. The mean value for SS-QOL Scale pretreatment for groups and B were 123.50 ± 18.98 and 121.05 ± 16.21 respectively. t-value was 0.52 and P = 0.607, Table 3 .
Comparison of the Mean Values of HAM-D Scale and SS-QOL Scale in Both Groups Post Treatment
There was a significant difference between both groups regarding HAM-D scale 
Comparison of the Mean Values of HAM-D Scale in both Groups before and after Treatment
There was a statistical significant difference for group (A) regarding HAM-D scale before and after treatment, p = 0.000. As, the mean values of HAM-D scale in group (A) pretreatment was 15.3 ± 3.82 and post treatment it improved significantly to 11.9 ± 4.87 and t-value was 6.24 Table 5 . But, there was no statistical 
Comparison of the Mean Values of SS-QOL Scale in Both Groups before and after Treatment
There was a statistical significant difference for group (A) regarding SS-QOL Scale before and after treatment, p = 0.000. As, the mean values of SS-QOL Scale in group (A) pretreatment was 123.50 ± 18.98 and post treatment it improved significantly to 144.70 ± 27.77 and t-value was 5.33 (Table 6 ). But, there was no statistical significant difference for group (B) regarding SS-QOL Scale before and after treatment, p = 0.66. As, the mean values of SS-QOL Scale in group (B) pretreatment was 121.05 ± 16.21 and post treatment was 124.05 ± 18.44, t-value was 1.2 and P = 0.243.
Discussion
Post-stroke depression (PSD) is a common affective disorder that can develop after stroke. Patients with PSD show poorer functional and recovery outcomes than patients with stroke who do not suffer from depression with higher risk of suicide [24] . Pharmacological treatments have limited efficacy and important adverse effects. Noninvasive neurostimulatory and neuromodulatory techniques; TMS and tDCS are rapidly emerging as a therapeutic strategy in various psychiatric disorders [25] . The current study results revealed that tDCS intervention caused a significant decrease in depression assessed by HDS in the actively treated group (A). Similar findings were observed by Valiengo et al. (2016) who used tDCS to the DLPFC of 23 patients with post-stroke depression and aphasia and found that their depressive symptoms decreased after four weeks [26] . Also, Valiengo et al. (2017) found that active tDCS was significantly superior with higher response and remission rates in 48 antidepressant-free patients with post-stroke depression [15] .
As, in depression there is prefrontal asymmetry with right prefrontal activity hyperactivity [27] . Thus the anode was positioned over the left DLPFC and the cathode over the right DLPFC. The anode stimulation is known to increase the excitability of cerebral cortex, while the cathode stimulation is known to suppress the excitability of the cerebral cortex [28] . It can be assumed that the improvement of depression was caused by tDCS might be due to the modulation of serotonergic and dopaminergic systems, which have traditionally been associated with the pathogenesis of affective disorders [25] .
In addition to the improvement in depression symptoms, the current study found a significant increase in the SS-QOL scale of the actively treated group In agreement with the results of current study Fregni et al. (2006) reported that repeated sessions of active tDCS do not result in cognitive impairment compared to placebo tDCS in patients with depression [33] . On the contrary, Fregni et al. (2006) reported an improvement in one aspect of cognitive function; working memory and this cognitive enhancement was not observed after sham tDCS and was not correlated with mood effects [33] . Also, Pisoni et al. (2018) found that anodal tDCS of the left DLPFC enhances cognitive performance in healthy subjects and such facilitation is supposed to be linked to the plastic changes at relevant cortical sites [34] .
In the current study there were no side-effects in the treated group. Similar findings were reported by Herrera-Melendez et al. (2019) , that tDCS is well tolerated, comparably easy to handle and cheap to use [25] .
Limitations and Strengths
This study has two limitations: 1) the results are difficult to generalize due to the small sample size, and 2) other factors influencing QOL have not been investigated.
The strength of this study includes; to our knowledge, this is one of few human studies to explore the effect of tDCS on post-stroke depression and using left DLPFC as stimulation site rather than as used in previous studies for treating depressive symptoms. However, questions still remain unanswered regarding the optimal stimulation parameters, positioning of electrodes, and the possible in- 
Conclusion
The current study showed that active tDCS to the DLPFC resulted in significant improvement of depressive symptoms, cognition, quality of life, social relationships, functional mobility and upper extremity function in post-stroke depression patients. Although further investigation is needed, the currently evidence supports the hypothesis that tDCS may constitute an effective treatment for depressive symptoms that bypasses the risks associated with antidepressants exposure, thus, tDCS may be a promising tool for treating post-stroke depressed patients.
